Alumis (ALMS) has drawn fresh attention after reporting positive topline Phase 3 ONWARD results for envudeucitinib in moderate to severe plaque psoriasis. All primary and secondary endpoints were met, ...
Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s ...
Alumis (ALMS) stock is soaring after the company announced positive trial results for its plaque psoriasis drug ...
Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...
Asianet Newsable on MSN
Why is ALMS stock rising today?
One Stocktwits user stated that now is a good time to buy the stock following the announcement of the trial results. Another ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback